Gabapentin Abuse Classification
Gabapentin abuse is NOT formally classified as a sedative-hypnotic use disorder in DSM-5, but it shares clinical features with this category and should be managed with similar caution, particularly in patients with substance use disorder history.
Current Diagnostic Framework
The DSM-5 does not include a specific diagnostic category for gabapentinoid use disorder 1. However, the FDA label explicitly acknowledges gabapentin's abuse and dependence potential, noting that it "does not exhibit affinity for benzodiazepine, opiate, or cannabinoid receptors" but still carries risk for misuse, particularly in individuals with poly-substance abuse history 2.
Why the Classification Question Matters
While gabapentin is pharmacologically distinct from traditional sedative-hypnotics (benzodiazepines, barbiturates, Z-drugs), it produces overlapping clinical effects:
- Sedation and CNS depression are prominent adverse effects 2
- Euphoria, sedation, and dissociation occur with misuse 3
- Tolerance and withdrawal symptoms develop with chronic use 2
- Respiratory depression occurs when combined with opioids 3
Practical Clinical Approach
If you encounter gabapentin abuse, diagnose it as "Other (or Unknown) Substance Use Disorder" using DSM-5 criteria 1. Apply the standard threshold of ≥2 criteria from the 11 DSM-5 substance use disorder criteria, with severity grading:
- Mild: 2-3 criteria
- Moderate: 4-5 criteria
- Severe: ≥6 criteria
Critical Caveat for Medical Use
Do NOT diagnose substance use disorder based solely on tolerance and withdrawal in patients taking gabapentin as prescribed for legitimate medical purposes 1. These represent normal physiological adaptations and require additional criteria for diagnosis.
Risk Stratification
Highest risk population: Patients with current or past substance use disorders, particularly:
- Opioid use disorder (most common association) 4, 5
- Poly-substance users 2, 6
- Those seeking euphoric effects or self-medicating withdrawal 5, 7
Pregabalin appears more addictive than gabapentin with faster onset of euphoria, more frequent behavioral dependence, and higher overdose lethality 5, 7.
Management Implications
When discontinuing gabapentin after prolonged use (>2 weeks), taper gradually with 10-25% weekly dose reductions 8. Abrupt cessation can precipitate withdrawal symptoms including agitation, disorientation, and confusion 2.
Monitor for dangerous drug combinations: Gabapentinoids combined with opioids or benzodiazepines significantly increase overdose risk through synergistic respiratory depression 3, 6, 4.
Bottom Line for Prescribers
While not formally a "sedative-hypnotic use disorder," gabapentin misuse should trigger the same clinical vigilance. In patients with substance use disorder history, avoid gabapentinoids if possible, or implement strict therapeutic monitoring with limited prescribing 5, 7. The growing evidence of harm—including increased hospitalizations and opioid-related mortality—demands appropriate caution 4.